Clinical Trials
5 trialsNCT04590963 2026-06-01
INTERLINK-1
AstraZeneca
Phase 3 Active not recruiting
NCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
NCT03822351 2024-10-08
COAST
MedImmune LLC
Phase 2 Completed
NCT03794544 2022-02-24
Neoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung Cancer
MedImmune LLC
Phase 2 Completed
NCT02557516 2019-12-17
Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL
Innate Pharma
Phase 1/2 Terminated